Pascoal Lab

@LabPascoal

Lab based at University of Pittsburgh interested in diagnostic and therapeutic approaches in neurodegeneration | PI: @TharickAPascoal

Pittsburgh, PA

pascoallab.org

Replies Reposts Media

Pinned
Pascoal Lab
@LabPascoal
May 28
We are pleased to announce the publication of top-line results from our HEAD study, on the comparison of tau PET tracers for the detection of tau pathology in Alzheimer’s disease, out now online in The Lancet. We are grateful to our collaborators on this work, and we look
Pascoal Lab
@LabPascoal
Aug 27
👇
VJDementia
@VJDementia
Aug 27
🧠 How could plasma p-tau217 transform the way participants are pre-screened and selected for Alzheimer’s disease clinical trials? At #AAIC26, @Pamlukasewicz (of @LabPascoal) discusses how plasma biomarkers could reduce reliance on costly PET scans and enable recruitment from
Pascoal Lab
@LabPascoal
Aug 20
👇
VJDementia
@VJDementia
Aug 20
At #AAIC2026, @Pamlukasewicz (of @LabPascoal) discusses a head-to-head comparison of flortaucipir and MK6240, highlighting the stronger association of plasma p-tau217 with MK6240 in early tau regions. 🎥 Watch here: ow.ly/JPJw50Zwelb #AlzheimersDisease #Dementia
Pascoal Lab
@LabPascoal
Aug 18
@Pamlukasewicz
VJDementia
@VJDementia
Aug 18
Could plasma p-tau217 streamline Alzheimer's disease clinical trial recruitment? 🧠 At #AAIC2026, @Pamlukasewicz (of @LabPascoal discusses how plasma p-tau217 could improve the cost-efficiency of AD trials by reducing the need for amyloid PET scans and accelerating participant
Pascoal Lab
@LabPascoal
Jul 29
👇👇
Tharick Pascoal
@TharickAPascoal
Jul 29
GFAP is not just an amyloid story. In 324 Aβ− patients with vascular disease, @markley_sojr linked plasma GFAP to medial temporal atrophy and worse cognition—supporting neuroinflammation as a potential target in VCI. In Neurology: doi.org/10.1212/WNL.00…